Ex vivo Expansion of CD56+ NK and NKT-like Lymphocytes from Peripheral Blood Mononuclear Cells of Patients with Ovarian Neoplasia

Ovarian cancer creates a suppressive microenvironment to escape immune elimination

(2010) Refika Yigit et al.   GYNECOLOGIC ONCOLOGY

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

(2009) Maria Berg et al.   CYTOTHERAPY

Immunotherapy of cancer

(2009) Hossein Borghaei et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Safety analysis ofex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study

(2009) Lisbeth Barkholt et al.   Immunotherapy

Natural killer cell-based immunotherapy in cancer: current insights and future prospects

(2009) T. Sutlu et al.   JOURNAL OF INTERNAL MEDICINE

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

(2008) E. Alici et al.   BLOOD

Human natural killer cells

(2008) M. A. Caligiuri   BLOOD

NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy

(2008) Karl-Johan Malmberg et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy

(2008) K.R Meehan et al.   CYTOTHERAPY